Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.
Tourmaline Bio
Status: Exited/Public
Antios Therapeutics
Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).
Jasper Therapeutics
Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.
Merged with Amplitude Healthcare Acquisition Corporation in 2021
Caribou Biosciences
Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Completed IPO in 2021
Arch Oncology
Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.
Immunocore
Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.
Completed IPO in 2021
Sentynl Therapeutics
Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.
Acquired by Zydus in 2017
Eyevance Pharmaceuticals
Commercial-stage specialty ophthalmic company focused on innovative and impactful branded prescription products targeting the anterior segment of the eye.
Acquired by Santen in 2020
Recent Comments